BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients.
August 28, 2026 10:49 AM EDT
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
Kyle LaHucik
Biotech Correspondent
BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their …
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected…
An experimental cancer vaccine by Moderna and Merck demonstrated positive outcomes in its first late-stage trial, advancing…
The Phase 3 INTerpath-001 trial delivered oncology's first personalised cancer vaccine win, and mRNA a therapeutic breakthrough…
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their…
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Biontech hat eine Studie für eine mRNA-basierte Therapie gegen eine bestimmte Art von Darmkrebs eingestellt. Die Aktie des…
